Sequential Rematching Randomization and Adaptive Monitoring with the Second-Generation p-value to increase the efficiency and efficacy of Randomized Clinical Trials

Jonathan Chipman, MS

Department of Biostatistics

Vanderbilt University

May 10, 2019

RCT Costs and Benefits

2015-2016 Pivotal Trials accepted by FDA **?**

- ▶ 138 Trials to approve 59 novel therapeutic drugs
- ▶ Enrolled on median 488 patients (IQR: 230, 740)
- ▶ Cost per patient on median $41K (IQR: $32K - $82K)
- ▶ 53 Used surrogate marker as primary endpoint

NINDS Reviewed costs of trials between 1977 and 2002

- ▶ Overall quality of life benefits $>>$ Overall costs

"Reducing the costs of trials is absolutely crucial for the public good" – Dr. Claiborne Johnston (UCSF) **?**

Outline

Three papers to increase study efficiency and efficacy.

- ▶ Motivating Example: REACH Trial
- ▶ Paper 1: Sequential Rematched Randomization
- ▶ Paper 2: Adaptive Monitoring Using the Second Generation p-value
- ▶ Paper 3: sgpvAM R package and practical guidance to control adaptive monitoring errors

3/36

REACH Trial

Rapid **E**ducation/Encouragement **A**nd **C**ommunications for **H**ealth

Population: Adults with Type 2 Diabetes (DM)

Purpose: Increase glycemic control and adherence to medications

Main Intervention: Text message-delivered diabetes support for 12 months

Outcome: Glycemic control (A1c) compared to control

Multi-site enrollment: 512 patients from Vanderbilt and Non-Vanderbilt Clinics

Clinical Relevance: Change clinical practice – Decrease in A1c of 0.5 or more

REACH

Did you take all of your diabetes meds today, Sun, 09/05? Please reply Y or N.

Key Baseline Covariates

Biological Factors

- ▶ Baseline A1c*
- ▶ Age at baseline
- ▶ Time since DM dx*
- ▶ DM type*
- ▶ Race / Ethnicity

* Greater association with outcome

Socio-economic Factors

- ▶ Yrs of education
- ▶ Income level
- ▶ Insurance type

Stratified Block Randomization

- Randomize within categories of similar patients (ex: Site)
- Continuous covariates must be categorized
- REACH Example: Randomize within site and Baseline A1c (6 strata)

| 6 Strata: Site & Baseline A1c | | |

Baseline A1c

	< 7	7-8	>8
Vanderbilt	43	87	158
Non-Vanderbilt	44	46	122

Stratified Block Randomization

- ▶ Limited in number of covariates creating strata
- ▶ 4000+ Strata - Stratifying on all covariates*
- ▶ 2 * 3 * 3 * 2 = 36 Strata - Stratifying on:
  - ▶ 2 Sites
  - ▶ 3 Baseline A1c levels
 - ▶ 3 DM Types
  - ▶ 2 Time since DM Dx levels

*Continuous baseline covariates categorized as:

Baseline A1c:	< 7	7-8	≥8
Age:	<60	≥60	
Yrs of Education:	<12	≥12	
Time since DM Dx:	<10	≥10	

Matched Randomization [?]

Observational Study: Randomization Trial:
Bipartite (2 group)   Non-bipartite matching
matching

Refined stratification into pairs of patients using distance matrix

- ▶ Pairs selected for smallest total distance
- ▶ Allows for any number of continuous and categorical covariates
- ▶ All participants known before randomization

Sequential Matching [?]

Sequential Matching [?]

Sequential Matching [?]

Sequential Matching [?]

Sequential Matching [?]

Matching OTF, some additional notes [?]

Pre-specification:

- ▶ Initial reservoir size
- ▶ Threshold to denote degree of similarity

Fixed Threshold: Match is better than [20%] of random matches

- ▶ Mahalanobis Distance of random pairs scales to $F_{(p, n-p)}$
- ▶ Assumes normally distributed baseline covariates

Reservoir:

- ▶ Not required to deplete
- ▶ May result in unequal treatment group sizes

Extension 1: Dynamic Threshold

Dynamic percentile of random match distances

1. Chance of matching now versus later
2. Random match distances (from data, ie not assumed normal)
3. Remove threshold at end to ensure all patients match

Patients enroll in b enrollment blocks
$||U_b||$: Number of unmatched patients at b^{th} enrollment
$||R_b||$: Number remaining patients after b^{th} enrollment

$$Q_b = \frac{||U_b|| - 1}{||U_b|| + ||R_b|| - 1}$$

$$Threshold_b = \begin{cases} F_b^{-1}(Q_b) & ||U_b|| < ||R_b|| \\ \text{best match(es)} & ||U_b|| \geq ||R_b|| \end{cases}$$

F_b is estimated by $\hat{F}_b$ by bootstrap sampling random matches from distance matrix.

Extension 2: Sequential Re-Matching

Sequential Matching

▶ Formed matches remain through study

Sequential Re-Matching

▶ Matches are allowed to break if a better match enters
▶ However, participants keep original treatment assignment
   ▶ New participant: Match to anybody
   ▶ Former enrolled participant: Match to anyone of opposite treatment
     or new participant

Case study using REACH Data to
comparing randomization schemes

Balance of baseline covariates
Efficiency estimating treatment effect

Results will vary based on baseline covariates

- ► Number of patients
- ► Number of covariates
- ► Distribution of covariates
- ► Adjusted R^2 of covariates

## Simulations to evaluate Sequential Rematching Randomization

Generate 20K MCMC replicates under potential outcomes framework:

- ▶ Bootstrap sample 512 observations from REACH trial
- ▶ Outcomes
  - ▶ Y(0) = Predicted three month A1c + random residual
  - ▶ Y(1) = Y(0) - 0.5
- ▶ Generate randomization scheme under
  - ▶ Block Randomization
  - ▶ Stratified Block Randomization
  - ▶ Matched Randomization
- ▶ Observe
  - ▶ Balance: Average Standardized Mean Difference among all covariates
 - ▶ Efficiency: CI Width of 1) fully-adjusted linear model and 2) Permutation distribution

Where Stratified and Matched randomization adjusts for

- ▶ Site, Baseline A1c, DM Type, and Time since DM Dx (Adj)
- ▶ All baseline covariates (3m A1c Adj $R^2 = 0.46$)

Average Standardized Mean Difference
(all baseline covariates)

**Covariate-Adjusted OLS Confidence Interval Width
of estimated treatment effect**

**Permutation Confidence Interval Width
of estimated treatment effect**

Recommendations regarding balance and efficiency

Conclusions

- ▶ Greatest overall balance by adjusting for all baseline covariates

- ▶ Greatest linear gains in efficiency
  - ▶ Model efficiency: adjusting randomization to all baseline covariates
  - ▶ Permutation efficiency: adjusting randomization to priority covariates

- ▶ Permutation efficiency achieves nearly same efficiency as fully-adjusted model with Block Randomization

Practical Recommendations

- ▶ Recommend adjusting to all baseline covariates
- ▶ Adaptively monitor until reaching a clear clinical conclusion

Paper 2: Adaptive Monitoring Using the Second Generation p-value

Prematurely Ending Clinical Trial(s)

Towards a Revolution in COPD Health (TORCH) (**?**)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in patients with chronic obstructive pulmonary disease

2007 6112 patients

- HR 0.825 (95% CI: 0.681-1.002, p-adjusted=0.052)
- Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'

Prematurely Ending Clinical Trial(s)

Towards a Revolution in COPD Health (TORCH) (**?**)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in patients with chronic obstructive pulmonary disease

2007 6112 patients

- HR 0.825 (95% CI: 0.681-1.000, p-adjusted=0.05)
- Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'

Prematurely Ending Clinical Trial(s)

Towards a Revolution in COPD Health (TORCH) (**?**)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in patients with chronic obstructive pulmonary disease

2007 6112 patients

- ▶ HR 0.825 (95% CI: 0.681-0.998, p-adjusted=0.0498)
- ▶ Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'

Second Generation p-value (SGPV; ?)

What proportion of interval overlaps with trivial effects?

$$\text{SGPV} = 0$$

$$\text{SGPV} = 1$$

$$\text{SGPV} = 0.5$$

Null Hypothesis

Interpretation of SGPV_T (T for trivial effects)

- $\text{SGPV}_T = 0.0$: Evidence to rule out trivial effects
- $\text{SGPV}_T = 1.0$: Evidence to rule out non-trivial effects
- $\text{SGPV}_T = 0.5$: Inconclusive, need more data

Second Generation p-value (SGPV; ?)

Example of indifferenze zone with TORCH

0.9   1   1.1
Hazard Ratio

If HR were 0.825 (95% CI: 0.681-0.899)
Interpretation of $SGPV_\tau = 0$: Rule out trivial effects

REACH

**R**apid **E**ducation/Encouragement **A**nd **C**ommunications for **H**ealth

-0.15 0 0.15
Treatment Effect

A decrease is HbA1c of 0.15 (ex. 7.5 to 7.35)
is considered essentially no change

REACH

Rapid Education/Encouragement And Communications for Health

A decrease is HbA1c of 0.5 (ex. 7.5 to 7.0)
would highly suggest adopting intervention

REACH

Rapid **E**ducation/Encouragement **A**nd **C**ommunications for **H**ealth

A decrease is HbA1c of between 0.15 and 0.5 is interesting
it may suggest adopting intervention

REACH

Rapid Education/Encouragement And Communications for Health

-0.50   -0.15 0 0.15   0.50
Treatment Effect

$SGPV_T$ to rule out trivial effects
$SGPV_{HA}$ to rule out highly-actionable effects

$SGPV_T = 0.0$: Ruled out trivial effects
$SGPV_{HA} = 0.0$: Ruled out highly actionable effects

Adaptive Monitoring with SGPV

Wait interval width stabilizes

Monitor interval and SGPV at desired looks

Alert $SGPV_T = 0.0$: Ruled out trivial effects

$SGPV_{HA} = 0.0$: Ruled out highly actionable effects

Affirm stop if same conclusion [40] patients later

end of resources ($n = 512$)

Report only the final interval when stopping

Adaptive Monitoring with SGPV

Wait interval width stabilizes

Monitor interval and SGPV at desired looks

Alert $SGPV_T = 0.0$: Ruled out trivial effects

$SGPV_{HA} = 0.0$: Ruled out highly actionable effects

Affirm stop if same conclusion [40] patients later

end of resources ($n = 512$)

Report only the final interval when stopping

Adaptive Monitoring with SGPV

     Wait interval width stabilizes

Monitor interval and SGPV at desired looks

    Alert $SGPV_T = 0.0$: Ruled out trivial effects

         $SGPV_{HA} = 0.0$: Ruled out highly actionable effects

  Affirm stop if same conclusion [40] patients later

         end of resources ($n = 512$)

  Report only the final interval when stopping

Adaptive Monitoring with SGPV

    Wait interval width stabilizes

Monitor interval and SGPV at desired looks

    Alert $SGPV_T = 0.0$: Ruled out trivial effects

          $SGPV_{HA} = 0.0$: Ruled out highly actionable effects

  Affirm stop if same conclusion [40] patients later

         end of resources ($n = 512$)

  Report only the final interval when stopping

Adaptive Monitoring with SGPV

Wait interval width stabilizes

Monitor interval and SGPV at desired looks

Alert $SGPV_T = 0.0$: Ruled out trivial effects

$SGPV_M = 0.0$: Ruled out highly actionable effects

Affirm stop if same conclusion [40] patients later

end of resources ($n = 512$)

Report only the final interval when stopping

Adaptive Monitoring with SGPV

Wait   interval width stabilizes

Monitor   interval and SGPV at desired looks

Alert $SGPV_T = 0.0$: Ruled out trivial effects

       $SGPV_{HA} = 0.0$: Ruled out highly actionable effects

Affirm   stop if same conclusion [40] patients later

       end of resources ($n = 512$)

Report   only the final interval when stopping

Adaptive Monitoring with SGPV

   Wait interval width stabilizes

Monitor interval and SGPV at desired looks

   Alert $SGPV_T = 0.0$: Ruled out trivial effects

        $SGPV_{HA} = 0.0$: Ruled out highly actionable effects

  Affirm stop if same conclusion [40] patients later

        end of resources ($n = 512$)

  Report only the final interval when stopping

Adaptive Monitoring with SGPV

Wait interval width stabilizes

Monitor interval and SGPV at desired looks

Alert $SGPV_T = 0.0$: Ruled out trivial effects

$SGPV_{HA} = 0.0$: Ruled out meaningful effects

Affirm stop if same conclusion [40] patients later

end of resources (n = 512)

Report only the final interval when stopping

Power; P (Reject Point Null)

Bias

Difference in Mean in A1c

Coverage

Paper 3: sgpvAM R package and practical guidance to control adaptive monitoring errors

sgpvAM package

1. How to easily operationalize?
2. Encourage not changing clinical relevance
3. Under fully sequentially monitored study, how long to wait to ensure Type I Error < 0.05?
4. What are operating characteristics when observations are not observed immediately? When limited in sample size?

sgpvAM package

sgpvAM package
1. Uses Valerie's spgv package on github
2. Vignette with examples
– Example 1-sided study with at most trivial effects $= 0.2$ and minimal highly actionable effect of 0.5, lag of 50 observations, will monitor no more frequently than 10 patients.

sgpvAM package

P(reject point null)
Required affirmation steps = 20
Unrestricted Sample Size

Wait Time
CI Width

- 0.2
- 0.2375
- 0.275
- 0.3125
- 0.35

$\mathfrak{O} \, \mathfrak{Q} \, \mathfrak{C}$

32/36

Average Sample Size
Required affirmation steps = 20
Unrestricted Sample Size

Wait Time
CI Width

- 0.2
- 0.2375
- 0.275
- 0.3125
- 0.35

sgpvAM package

P(inconclusive)
Wait for expected CI width = 0.35
50 Lag outcomes

sgpvAM package

Type I Error ; P (Reject Point Null | Theta = 0)

sgpvAM package

P (Inconclusive after lag 50 observations | Theta = Midpoint between Trivial and Impactful Deltas)

References